MENU
Go to the list of all blogs
Anna G's Avatar
published in Blogs
Apr 19, 2023

Organon & Co (OGN, $23.59) was one of the top losers in Q1, experiencing a decrease of 25.36%

The integration of AI in the stock market has opened up new opportunities for traders and investors to make well-informed decisions. Specifically, in the case of Organon & Co (OGN), Tickeron's Swing Trader for Beginners: Search for Trend Reversals (TA&FA) bot has been a top performer in their robot factory. Traders can access this bot through the Tickeron website and gain valuable insights into potential trading opportunities. By utilizing AI and technical analysis, the bot provides recommendations for buying and selling AI stock. 


Organon & Co (OGN) has seen a rough start to the year, with the stock falling -25.36% over the last three months to $23.59 per share. However, the latest analysis from A.I.dvisor reveals that OGN could be ready for a rebound.

A.I.dvisor analyzed 57 stocks in the Pharmaceuticals: Major Industry for the 3-month period ending April 18, 2023, and found that 58.82% exhibited an Uptrend while 41.18% demonstrated a Downtrend. Despite OGN's recent decline, traders should take note of the Momentum Indicator turning positive on March 28, 2023. This shift indicates that the stock could be entering a new upward trend.

If the Momentum Indicator's past performance is any indication, traders may want to consider buying OGN stock or call options. Tickeron's A.I.dvisor analyzed 28 similar instances where the indicator turned positive, and in 21 of those cases, the stock moved higher in the following days. The odds of a move higher this time are at an impressive 75%.

Despite the recent dip, the positive Momentum Indicator coupled with the favorable odds for a move higher could make Organon & Co an attractive investment opportunity for traders. As always, it's important to conduct thorough research and analysis before making any investment decisions.

Our platform utilizes the power of AI to provide you with valuable insights and analysis, helping you make informed decisions when it comes to trading and investing. Don't miss out on this opportunity to take your stock market game to the next level. Register with us now and start making money! If you're interested in stocks and want to stay ahead of the game, consider registering with us, click here.

Related Ticker: OGN

OGN in upward trend: price rose above 50-day moving average on January 07, 2025

OGN moved above its 50-day moving average on January 07, 2025 date and that indicates a change from a downward trend to an upward trend. In of 22 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 31, 2024. You may want to consider a long position or call options on OGN as a result. In of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for OGN just turned positive on December 26, 2024. Looking at past instances where OGN's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OGN broke above its upper Bollinger Band on January 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for OGN entered a downward trend on January 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (5.632). P/E Ratio (4.637) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.060) settles around the average of (0.164) among similar stocks. P/S Ratio (0.757) is also within normal values, averaging (3.643).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 0%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -7%. ORINY experienced the highest price growth at 12%, while KYKOF experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was 37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 26
P/E Growth Rating: 70
Price Growth Rating: 64
SMR Rating: 60
Profit Risk Rating: 77
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
OGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
30 Hudson Street
Phone
+1 551 430-6900
Employees
10000
Web
https://www.organon.com